Interestingly, an aptamer blocking SARS-CoV-2 spike–TLR4 interaction selectively inhibits SARS-CoV-2-induced inflammation [64], strongly suggesting that, in addition to TRL2, TLR4 should be considered a biochemical target for COVID-19 therapy [64,65]. The gene discussed is TLR4; the disease is COVID-19.